Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy

by Raffaella Ravinetto, Daniel Vandenbergh, Cécile Macé et al.
Journal of Pharmaceutical Policy and Practice, 2016 9:36 – Published: 10 November 2016

4 pp. 350 kB
https://joppp.biomedcentral.com/track/pdf/10.1186/s40545-016-0088-0?
site=joppp.biomedcentral.com
2

The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries. Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed.

(Visited 29 times, 1 visits today)
This entry was posted in Essential Medicines, General. Bookmark the permalink.